Research suggests that jamun may have potential for supporting blood sugar regulation, with laboratory evidence indicating that an extract from jamun pomace can inhibit α-amylase, an enzyme involved in breaking down dietary starches into sugars and a recognized target in type 2 diabetes management. The single available study, a 2025 lab-based investigation using enzyme assays and computational modeling, found that the pomace extract showed inhibitory potency reasonably comparable to acarbose, a prescription drug used for blood sugar control, though the two compounds appear to work through different mechanisms. It is important to note that the current evidence is limited to preliminary laboratory and computer-based methods, with no human clinical trials or animal studies included in this body of research, meaning it is not yet known whether these findings would translate to meaningful effects in people. Studies indicate this is an early-stage area of research, and while the results are promising enough to warrant further investigation, conclusions about real-world efficacy cannot yet be drawn.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Comprehensive analysis of Syzygium cumini L. pomace extract as an α-amylase i... | Other | 2025 | Supports | 72 |